3 November 2014EuropeRichard Bassett and Richard Wells
The Nagoya Protocol and what it means for the EU
The Nagoya Protocol implements an objective of the Convention on Biological Diversity (CBD), which aims to provide an international framework for safeguarding the conservation and sustainability of biodiversity, and in particular genetic resources. The protocol requires that, if a genetic resource, or traditional knowledge (TK) associated with such a resource, is used, consent must be received from the country in which it is found and from any local community that claims custodianship over it. In the rest of this article, we shall refer just to the genetic resource, but it should be understood that TK may be involved as well. The user of the genetic resource must also provide fair compensation based on any benefit that it has received from the genetic resource. This is generally referred to as access and benefit sharing (ABS).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
19 June 2026 The court overturns a decision granting the German-based company provisional measures and ordering a Chinese medtech rival to stop selling its device in four European countries.
16 June 2026 In the second of a series of interviews with women judges at the pan-European court, Ulrike Voß talks to Sarah Speight about her career, her views on the court so far, and how more women could be encouraged to join the judiciary.
11 June 2026 The UPC has dealt Siemens a loss against a rival US medtech company, upholding a key breast imaging patent and addressing a range of issues from infringement and validity to recall orders and software-based workarounds.